


Supplementary Table 1. Addition of taxane administration frequency to the p16Age Gap-driven model does not change model performance.

Variable	Estimate	p
p16Age Gap	-0.047	0.01
<i>p16</i> pre-chemo	1.25	0.04
Taxane type [paclitaxel]	0.88	0.002
Taxane frequency [weekly]	-0.24	0.32
Model Performance		
AICc	158	
BIC	172	
Chi-square	29.5	
p value	0.0001	

Supplementary Table 2. Dose reduction and discontinuation due to toxicities.

	All N=152	Grade 2+ CIPN n=44	No CIPN n=108
Dose reduction, n (%)	46 (30)	18 (41)	28 (26)
Dose discontinuation, n (%)	22 (14)	10 (23)	12 (11)

Supplementary Figure 1



Supplementary Figure 1. P16Age Gap does not differ between participant groups whose taxane regimen was discontinued or reduced due to chemotherapy toxicity.